Cost-Effectiveness of the Next Generation Nonavalent Human Papillomavirus Vaccine in the Context of Primary Human Papillomavirus Screening in Australia: A Comparative Modelling Analysis

The Lancet Public Health - United Kingdom
doi 10.1016/s2468-2667(16)30019-6

Related search